Common use of Securities Act Liabilities Clause in Contracts

Securities Act Liabilities. Indemnitee acknowledges that paragraph (h) of Item 512 of Regulation S-K promulgated under the Securities Act of 1933, as amended (the “Act”), currently generally requires the Company to undertake in connection with any registration statement filed under the Act to submit the issue of the enforceability of Indemnitee’s rights under this Agreement in connection with any liability under the Act on public policy grounds to a court of appropriate jurisdiction and to be governed by any final adjudication of such issue.

Appears in 5 contracts

Sources: Indemnification Agreement (MetaVia Inc.), Indemnification Agreement (Gemphire Therapeutics Inc.), Indemnification Agreement (Gemphire Therapeutics Inc.)

Securities Act Liabilities. Indemnitee acknowledges that paragraph (h) of Item 512 of Regulation S-K promulgated under the Securities Act of 1933, as amended (the “Act”), currently generally requires the Company to undertake to submit, in connection with any registration statement filed under the Act to submit Act, the issue of the enforceability of Indemnitee’s rights under this Agreement in connection with any liability under the Act on public policy grounds to a court of appropriate jurisdiction and to be governed by any final adjudication of such issue.

Appears in 1 contract

Sources: Indemnification Agreement (Rexahn Pharmaceuticals, Inc.)

Securities Act Liabilities. Indemnitee acknowledges that paragraph (h) of Item 512 of Regulation S-K promulgated under the Securities Act of 1933, as amended (the “Act”), ) currently generally requires the Company to undertake in connection with any registration statement filed under the Act to submit the issue of the enforceability of Indemnitee’s rights under this Agreement in connection with any liability under the Act on public policy grounds to a court of appropriate jurisdiction and to be governed by any final adjudication of such issue.

Appears in 1 contract

Sources: Indemnity Agreement (Ambit Biosciences Corp)